Topic Listing for BioCryst Pharmaceuticals

Acceleration Accrued Expenses
Accumulated Other Comprehensive Income Additional Products
Administration Plan Aggregate Option Exercises 2004 Year-end Values
Aggregate Option Exercises 2005 Year-end Values Amendment Termination
Amendments Amendments Articles Incorporation Bylaws Change
Annual Incentive Compensation Anti-takeover Provisions Corporate Charter Documents Result Outcomes Not
Appointment Jon Stonehouse Chief Executive Officer Approval Stock Incentive Plan
Audit Committee Audit Committee Report
Audit Fees Automatic Option Grant Program
Available Information Background
Base Salary Basis Presentation
Bcx-4208 Because Hazardous Materials Violate Environmental Controls Regulations Apply
Because Stock Ownership Concentrated Other Investors Limited Influence Because Stock Ownership Concentrated Other Investors Minimal Influence
Beneficial Ownership Reporting Compliance Biocryst
Biocryst Advances Lead Product Program Initiates Intravenous Oral Biocryst Announces Early Termination Hart-scott-rodino Waiting Period Roche
Biocryst Announces Fda Approval Initiate Human Testing Intravenous Biocryst Announces Presentation Fodosine Data 47th Annual Meeting
Biocryst Appoints Stephen Biggar Board Directors Biocryst Initiates Bcx-4208 Oral Phase Clinical Trial Healthy
Biocryst Initiates Fodosine Oral Phase Clinical Trial Patients Biocryst Initiates Intravenous Phase Clinical Trial Fodosine Patients
Biocryst Mundipharma International Holdings Limited Collaborate Development Fodosine Biocryst Pharmaceuticals Appoints Jonathan Nugent Vice President Corporate
Biocryst Pharmaceuticals Inc Biocryst Pharmaceuticals Inc Condensed Statements Operations 2005 2004
Biocryst Pharmaceuticals Inc Exact Name Registrant Specified Charter Biocryst Pharmaceuticals Inc Proxy Annual Meeting Stockholders 2005
Biocryst Presents Forodesine Clinical Data International Symposium Leukemia Biocryst Receives Fda Fast Track Designation Peramivir
Biocryst Receives Fda Fast Track Status Fodosine Treatment Biocryst Reports 2005 Financial Results
Biocryst Reports 2006 Financial Results Biocryst Reports Year-end 2004 Financial Results
Biocryst Reports Year-end 2005 Financial Results Biocrysts Notice Annual Meeting Proxy Statement Report Other
Birmingham Alabama -february 2005 Birmingham Alabama 2006 Biocryst Pharmaceuticals Inc Nasdaq Bcrx
Board Recommends Stockholders Vote Ratification Appointment Ernst Young Business Strategy
Capital Stock Cash Equivalents
Certain Relationships Related Transactions Certain Risk Factors Affect Future Results Financial Condition
Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act Certifications
Changes Internal Control Over Financial Reporting Charles Bugg Phd Retire 2007 Become Non-executive Chairman
Chief Executive Officer Clinical Trials Drug Candidates Fail Not Marketed Result
Clinical Trials Drug Product Candidates Fail Not Marketed Collaboration In-license Relationships
Collaborative Agreements Collaborative Other Research Development Contracts
Committees Board Compared 2002
Compared 2003 Compared 2004
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Committee Report Executive
Competition Computer Systems Fail Business Suffer
Computer Systems Fail Facility Incurs Damage Business Suffer Concentration Credit Market Risk
Conference Call Consent Independent Registered Public Accounting Firm
Contractual Obligations Controls Procedures
Corporate Alliances Corporate Governance
Corporate Governance Nominating Committee Corporate Highlights
Corporate Overview Corporate Transactions Changes Control
Corporate Update Critical Accounting Policies
Current Development Strategy Current Development Strategy T-cell Leukemia B-all Cll Ctcl
Date 2005 Financial Results Date 2006 Financial Results
Date Report 2005 Date Report 2006
Date Report 2007 Deductibility Executive Compensation
Deferred Taxes Departure Directors Principal Officers Election Appointment
Development Collaborations Other Parties Fail Drug Candidates Delayed Development Collaborations Other Parties Fail Drug Product Candidates
Development Intravenous Intramuscular Dosing Peramivir Avian Flu Subject Director Attendance
Director Compensation Directors
Directors Terms Expiring Annual Meeting Stockholders 2010 Directors Terms Expiring Annual Meeting Stockholders 2011
Discretionary Option Grant Program Documents Incorporated Reference
Drug Candidates Not Achieve Broad Market Acceptance Business Drug Product Candidates Not Achieve Broad Market Acceptance
Effective Date Term Plan Eligibility
Employee Benefit Plans Employee Stock Purchase Plan
Employment Agreement Ceo Employment Agreements Change Control Arrangements
Employment Agreements Other Named Executive Officers Entry Material Definitive Agreement
Equity Compensation Plan Information Equity Incentive Programs
Estimates Evaluation Disclosure Controls Procedures
Exact Name Registrant Specified Charter Except
Executive Compensation Executive Officers
Exhibits Face Clinical Trial Liability Claims Related Misuse Compounds
Face Intense Competition Unable Compete Effectively Demand Products Fail Adequately Protect Enforce Intellectual Property Rights Secure
Fail Establish Collaborative Relationships Commercialize Certain Drug Product Fail Obtain Additional Financing Unable Complete Development Commercialization
Fail Retain Existing Key Personnel Attract Additional Development Federal Income Tax Consequences
Financial Results Financial Statements
Financial Statements Exhibits Following Report Audit Committee Not Constitute Soliciting Material
Form 10-k Form 10-q
Former Merck Kgaa Astrazeneca Executive Succeed Founder Charles Former Name Address Changed Since Last Report
Forward-looking Statements Forward-looking Statements Risk Factors
Full 2004 Financial Results Full 2005 Financial Results
Furniture Equipment General
General Information General Provisions
Government Regulation Hepatitis Polymerase Inhibitors
Human Resources Income Taxes
Incorporation Reference Incurred Substantial Losses Since Inception 1986 Expect Continue
Independent Registered Public Accounting Firm Index
Index Exhibits Influenza
Information Regarding Forward-looking Statements Jon Stonehouse Appointed Chief Executive Officer Biocryst
Lease Obligations Other Contingencies Licensees Not Obtain Maintain Governmental Approvals Products Development
Liquidity Capital Resources Long-term Equity Incentive Awards
Managements Discussion Analysis Financial Condition Results Operation Managements Report Internal Control Over Financial Reporting
Market Registrants Common Equity Related Stockholder Matters Issuer Marketable Securities
Marketing Sales Medicare Prescription Drug Coverage Legislation Future Legislative Regulatory
Miscellaneous Miscellaneous Provisions
Name Person Filing Proxy Statement Other Registrant Narrative Director Compensation Table
Net Loss Per Share Neuraminidase Inhibitor Peramivir
Never Paid Dividends Common Stock Not Anticipate Doing New Plan Benefits
Nine-month Results Nominees Terms Expiring Annual Meeting Stockholders 2012
Not Commercialized Products Technologies Future Revenue Generation Uncertain Notice Annual Meeting Stockholders Held 2005
Notice Annual Meeting Stockholders Held 2006 Novel Oral Small Molecule Demonstrates Safety Healthy Volunteers
Number 000-23186 Off-balance Sheet Arrangements
Officers Option Exercises Stock Vested
Option Grants Option Grants 2004
Option Grants 2005 Oral Intravenous Formulations Advance Clinical Trials
Other Elements Compensation Other Events
Other Events Regulation Disclosure Other Matters
Overview Part Other Information
Patents Licenses Patents Proprietary Information
Philosophy Overview Compensation Pipeline Highlights
Pnp Inhibitor Pnp Inhibitor Bcx-4208
Pnp Inhibitor Fodosine Policy Regarding Tax Deductibility Compensation
Policy Respect Equity Compensation Awards Previous Clinical Development History
Principal Accounting Fees Services Products Development
Properties Proxy Statement
Proxy Statement Pursuant Securities Exchange Act 1934 Psoriasis
Purposes Plan Pursuant 151 General Corporation Law State Delaware
Quantitative Qualitative Disclosures Market Risk Quarterly Financial Information Except Per Share
Ratification Appointment Independent Registered Public Accountants Recent Accounting Pronouncements
Recent Medicare Prescription Drug Coverage Legislation Future Legislative Reclassifications
Recommendation Board Directors Registrants Telephone Number Including Area Code
Regulation Disclosure Relationships Independence Compensation Committee Members
Remainder Page Intentionally Left Blank Report Independent Registered Public Accounting Firm Financial Statements
Report Independent Registered Public Accounting Firm Internal Control Required Vote
Research Development Research Development Expenses
Resignation Charles Bugg Phd Chief Executive Officer Results Operations 2005 Compared 2004
Results Operations 2006 Compared 2005 Results Operations Financial Condition
Revenue Recognition Risk Factors
Role Compensation Consultants Role Executive Officers
Schedule 14a Rule 14a-101 Information Required Proxy Statement Scientific Advisory Board Consultants
Securities Held-to-maturity Securities Registered Pursuant Act
Security Ownership Certain Beneficial Owners Management Selection Board Nominees
Share Escrow Legends Share Reserve
Share Rights Awards Signatures
Special Retention Incentives Special Retention Stock Option Grants
Special Tax Election Stock Appreciation Rights
Stock Issuance Program Stock Issuances
Stock Price Likely Highly Volatile Value Investment Decline Stock-based Compensation
Stockholder Communications Stockholder Proposals
Stockholders Structure-based Drug Design
Study Design Subsequent Events
Substantial Risk Product Liability Claims Business Unable Obtain T-cell Related Diseases
Table Contents Terms Options
Tissue Factor Viia Inhibitors Title Each Class Common Stock Par Value
Unable Establish Sales Marketing Distribution Capabilities Necessary Successfully Users Drug Products Not Reimbursed Future Sales Decline
Valuation Valuation Financial Instruments
Vote Phone 1-800-690-6903 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki